Month: April 2025

Apr 30 2025

Uncategorized

MERIT Therapy for Schizophrenia and Serious Mental Illness

by Clinical Editor

No Comments

MERIT is one of several metacognitive psychotherapies, designed especially to meet the needs of individuals living with serious mental illnesses, including schizophrenia. It is deliverable in both …

Apr 30 2025

Uncategorized

Cannabis Use Disorder Linked to Psychosis Brain Changes

by Clinical Editor

No Comments

New research shows that individuals with cannabis use disorder have elevated dopamine levels in brain regions associated with psychosis.

Apr 29 2025

Uncategorized

Could eye scans spot schizophrenia early? New research offers hope for early detection

by Clinical Editor

No Comments

Eyes have long been called a window to the world — but new research suggests they may also reveal the state of a person’s mental health. New study by a...

Apr 29 2025

Uncategorized

Defense secretary orders review of medical standards for military enlistment

by Clinical Editor

No Comments

Defense Secretary Pete Hegseth signed a memorandum, April 24, 2025, directing a comprehensive review of medical conditions that …

Apr 28 2025

Uncategorized

Cobenfy as an Adjunctive Agent in Schizophrenia: Peter J. Weiden, MD, Shares Insights on the Latest Findings – Psychiatric Times

by Clinical Editor

No Comments

Cobenfy as an Adjunctive Agent in Schizophrenia: Peter J. Weiden, MD, Shares Insights on the Latest Findings  Psychiatric Times

Apr 28 2025

Uncategorized

Neuroleptic Malignant Syndrome Following Brexpiprazole Initiation in a Treatment-Resistant Schizophrenia Patient With Influenza A: A Case Report – Cureus

by Clinical Editor

No Comments

Neuroleptic Malignant Syndrome Following Brexpiprazole Initiation in a Treatment-Resistant Schizophrenia Patient With Influenza A: A Case Report  Cureus

Apr 27 2025

Uncategorized

Bristol Myers’ Cobenfy fails in key study as add-on treatment for schizophrenia

by Clinical Editor

No Comments

By Sriparna Roy (Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that would help expand...

Apr 27 2025

Uncategorized

Substance-Induced vs Primary Psychosis: Are They Different?

by Clinical Editor

No Comments

Are substance-induced psychosis and primary psychosis fundamentally different? And if they are, does it matter?

Apr 26 2025

Uncategorized

BMS shrugs off Cobenfy’s schizophrenia hit as it gears up for Alzheimer’s psychosis readout, 7 trial starts

by Clinical Editor

No Comments

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the...

Apr 26 2025

Uncategorized

Bristol Myers’ schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan

by Clinical Editor

No Comments

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. | Schizophrenia drug...